Systemic psoriasis therapeutics: Key market research findings
- The Americas dominate the market geographically
- Biologics to account for a majority share of the market’s revenue
- Key vendors – AbbVie, Johnson & Johnson, Celgene, Amgen, and Pfizer
Technavio’s market research analysts predict the global systemic psoriasis therapeutics market to grow at a CAGR of more than 9% between 2016 and 2020. The growth of the market is spurred by the anticipated approval of late-stage pipeline molecules. The clinical pipeline for psoriasis drugs is moderately strong with the emergence of more therapies, featuring candidates in different stages of development, including drugs with better safety and efficacy profiles. During 2015, the Americas dominated the global systemic psoriasis therapeutics market by accounting for a market share of around 53%. Factors such as the increasing prevalence of psoriasis, higher uptake of current biologic drugs, and the launch of novel biologics will further fuel growth in the systemic psoriasis therapeutics market in the Americas during the forecast period.
The new market research report from Technavio presents a breakdown and analysis of the systemic psoriasis therapeutics segments based on the type of molecule.
“The emergence of next-generation systemic psoriatic therapies is a trend that will reflect positively on the market in the coming years. Several classes of novel oral therapies are emerging with a sophisticated approach to treating psoriasis. CF101 is an A3 adenosine receptor agonist, an advanced small molecule administered orally, which has shown a favorable therapeutic index during its Phase II clinical trials in treating the condition,” says Barath Palada, Lead Analyst, Pharma, Technavio Research.
By 2020, the biologics segment will continue its dominance as the primary revenue generator in the global systemic psoriasis therapeutics market by accounting for more than 92% of the market share. The biologics segment consists of medicinal products that are extracted from biological sources such as humans, animals, or microorganisms and manufactured biotechnologically. Biologics include products such as enzymes, allergens, blood and blood components, gene therapy, recombinant proteins, somatic cells, tissues, and vaccines to treat various diseases.
The key vendors in the global systemic psoriasis therapeutics market include AbbVie, Johnson & Johnson, Celgene, Amgen, and Pfizer. The global systemic psoriasis therapeutics market is highly competitive and is characterized by the presence of key vendors, such as AbbVie, Johnson & Johnson, Celgene, Amgen, and Pfizer. Humira, a drug by AbbVie has maintained a strong presence in the market, particularly in North America and Europe. The drug is the only biologic approved in Europe to treat children with the condition. The competitive environment in this market is expected to intensify with an increase in product or service extensions. The competition among the vendors is expected to increase as they enter into partnerships or acquire distributors to increase their sales and expand their businesses worldwide.
A more detailed analysis is available in the Technavio report, Global Systemic Psoriasis Therapeutics Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
